# A Positive Outcome and Literature Review of Acute Myeloid Leukaemia in Pregnancy

## TL;DR

This paper discusses the management of a rare case of AML during pregnancy, emphasizing the importance of timely treatment and multidisciplinary care to ensure maternal and fetal safety.

## Contribution

The paper presents a case of AML with NPM1 mutation during pregnancy and highlights management strategies based on WHO guidance.

## Key findings

- The patient delivered a morphologically normal fetus after an elective caesarean section at 33 weeks.
- AML treatment should not be delayed, and decisions must balance maternal and fetal outcomes.
- Collaboration with obstetric and neonatal teams is essential for successful management.

## Abstract

Acute myeloid leukaemia (AML) in pregnancy is rare and difficult to manage. Here, we describe a case of AML with NPM1 mutation. The patient was counselled regarding the therapy-attributable risks, underwent an elective caesarean section at 33 weeks’ gestation, and delivered a morphologically normal fetus. As per WHO guidance, AML treatment should not be delayed. Management requires close collaboration with obstetric and neonatal teams, striking a balance between maternal and foetal survival. Counselling on elective termination should be provided. Treatment decisions should reflect gestational age at diagnosis, maternal tolerance, and drug toxicity. The aim is to complete pregnancy with a viable, healthy fetus and with minimal harm to the mother.